Related Experiment Video

Updated: Apr 1, 2026

Targeting Cysteine Thiols for in Vitro Site-specific Glycosylation of Recombinant Proteins
11:25

Targeting Cysteine Thiols for in Vitro Site-specific Glycosylation of Recombinant Proteins

Published on: October 4, 2017

7.2K

Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors

Minh V Huynh, Sharon L Campbell1

  • 1Department of Biochemistry and Biophysics, University of North Carolina School of Medicine, Chapel Hill, NC, USA. campbesl@med.unc.edu.

Mini Reviews in Medicinal Chemistry
|October 2, 2015
PubMed

Insights

Targeting KRAS G12C, a specific cancer-driving mutation, is now possible with novel cysteine-directed inhibitors. Understanding KRAS G12C

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Directly inhibiting oncogenic RAS proteins has been challenging for over 30 years.
  • No clinically relevant therapies currently exist for RAS-driven cancers.
  • Recent advancements include small molecule inhibitors targeting cysteine-containing RAS mutants.

Purpose of the Study:

  • To review the development and targeting strategies of novel cysteine-directed RAS inhibitors.
  • To compare the oncogenic potency of KRAS G12C with other KRAS G12 mutants.
  • To explore the role of KRAS G12C redox properties in tumorigenesis and drug efficacy.

Main Methods:

  • Literature review of cysteine-directed RAS inhibitors.
  • Comparative analysis of oncogenic potency of KRAS mutants.
  • Evaluation of redox properties and their impact on signaling and drug targeting.

Main Results:

  • Two classes of selective small molecule inhibitors targeting KRAS G12C have been developed.
  • KRAS G12C exhibits variable oncogenic potency compared to other KRAS G12 mutants.
  • Redox properties of KRAS G12C may influence its signaling, tumorigenic potential, and inhibitor efficacy.

Conclusions:

  • Cysteine-directed inhibitors represent a significant advancement in targeting oncogenic KRAS.
  • Understanding KRAS G12C's unique properties is crucial for optimizing therapeutic strategies.
  • Further research into redox modulation could lead to improved directed oncogenic RAS inhibitors.

More Related Videos

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay06:17

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

1.4K
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
84
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
620
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.3K